[Rubidazone (22 050 RP): clinical study. Phase II trial in solid tumors and lymphomas (author's transl)].

Abstract

Rubidazone is a semisynthetic antibiomitotic close to daunorubicin and doxorubicin. Fifty two patients with various advanced cancers received rubidazone intravenously at the initial unitary dose of 200 mg/m2 in a single injection at three week intervals; this base line dosage had been adapted in function of leuko-platelet variations observed between the… (More)

Topics

Cite this paper

@article{Chauvergne1978Rubidazone0, title={[Rubidazone (22 050 RP): clinical study. Phase II trial in solid tumors and lymphomas (author's transl)].}, author={Jacques Chauvergne and Paul Cappelaere and M. J. Carton and J. Gary-Bobo and Tirza Klein}, journal={Bulletin du cancer}, year={1978}, volume={65 1}, pages={19-24} }